Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of Moderate Buy by Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to […]

Related Keywords

United States ,Piper Sandler ,Hermes Inc ,Tower Research Capital ,Cetera Advisor Networks ,Needham Company ,Cara Therapeutics Inc ,Jag Capital Management ,Sigma Securities ,Nasdaq ,Cara Therapeutics ,Get Free Report ,Research Capital ,Advisor Networks ,Capital Management ,Two Sigma Securities ,Get Free ,Cara Therapeutics Daily ,Nasdaq Cara ,Cara ,Medical ,Ratings ,Consensus ,